摘要
目的评价口服脊髓灰质炎(脊灰)减毒活疫苗(人二倍体细胞)[Oral Poliomyelitis Attenuated Live Vaccine(Human Diploid Cell),OPV(HDC)],在≥2月龄儿童中的安全性和免疫原性。方法采用随机、盲态、对照的原则进行设计,1200名2～5月龄婴儿随机接种OPV(HDC)和对照疫苗,用抗脊灰病毒中和抗体试验检测免疫前、后抗体。结果接种3剂OPV(HDC)后全身反应轻微,全程免疫后1个月,Ⅰ、Ⅱ、Ⅲ型中和抗体免疫成功率分别为98.28%、95.32%、95.34%;免疫后易感人群的Ⅰ、Ⅱ、Ⅲ型中和抗体几何平均滴度,分别为1∶1243.72、1∶234.38、1∶273.10。结论 OPV(HDC)在≥2月龄儿童中具有良好的安全性和免疫原性。
Objective To evaluate the safety and Immunogenicity of the Poliomyelitis vaccine（Human Diploid Cell） in≥2 month-old children.MethodsA random,blind and control trial,1200 healthy children of 2～5 months old in Jiangsu province were administered OPV（HDC） vaccine and control vaccines.The antibody was tested by neutralization test.ResultsAfter 3 doses of the OPV（HDC） vaccine,the systemic reactions were mild.After 1 month of vaccination with 3 doses of the OPV（HDC） vaccine,the immune success rates of Ⅰ、Ⅱ、Ⅲ type were 98.28%、99.45%、and 95.71% respectively,the GMTs of Ⅰ、Ⅱ、Ⅲ type in susceptible children were 1：1243.72、1：234.38 and 1：273.10 respectively.ConclusionsThe OPV（HDC） vaccine was safe and immunogenicity for the children≥2 months old.
出处
《中国疫苗和免疫》
CAS
2010年第3期193-196,共4页
Chinese Journal of Vaccines and Immunization
